Abbott Laboratories Corporation

Abbvie Inc.

Other

Yu-Ming M Pu

Yi-Yin Ku

Marlon D Cowart

Timothy A Grieme

Alan C Christesen

Robert J Altenbach

Lawrence A Black

Gregory A Gfesser

Huaqing Liu

Ramin Faghih

Kirill A Lukin

Mathew M Mulhern

Sou-Jen Chang

Diana L Nersesian

Vincent S Chan

Michael P Curtis

Padam N Sharma

Youssef L Bennani

Daniel J Plata

Ashok K Gupta

Dale J Kempf

Rolf Wagner

Clarence J Maring

Howard E Morton

Pamela L Donner

Steven A King

Vincent S Stoll

Jean-Christophe C Califano

Steven Cramer Cullen

Jufang Barkalow

Elaine C Lee

Alan C Christensen

Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein.

Processes for the preparation of an apoptosis-inducing agent

A process for the preparation of compounds of formula (I) or a salt thereof wherein X, X, X, X, R, u, R, R, z, and Aare as defined in the specification is disclosed.

Process for preparing cannabinoid receptor ligands

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Bicyclic-substituted amines as histamine-3 receptor ligands

The present invention provides HCV polymerase inhibiting compounds having the formula (I):  where Ris cyclobutyl-N(R)&#x2014;, n is 1, 2, 3 or 4, and at least one Ris RSON(R)alkyl-. In a non-limiting example, a compound of the present invention is N-[(3-{1-[(cyclobutyl)amino])-4-hydroxy -2-oxo-1,2-dihydro-quinolin-3-yl}-1,1-dioxo-1,4-dihydro-1&#x3bb;-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide. The present invention also features compositions comprising the compounds of the present invention or pharmaceutically acceptable salts, stereoisomers or tautomers thereof, and methods of using the same to treat or prevent HCV infection.

Anti-infective agents

The present invention relates to salts of 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one, processes for their preparation, pharmaceutical compositions comprising such compounds, method of using them, and a process for preparing the active agent.

2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation

Compounds of formula (I) wherein Ror Ris an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by Land L, to a heteroaromatic core, and X, X', Y, Y&#x2032;, Z, Z&#x2032;, R, R, R, R, R, R, R, L, L, and Lare as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Bicyclic-substituted amines having cyclic-substituted monocyclic substituents

The present invention relates to processes for preparing amine substituted benzofurans, and more particularly 4-(2-&lcub;2-&lsqb;(2R)-2-methyl-1-pyrrolidinyl&rsqb;ethyl&rcub;-1-benzofuran-5-yl)benzonitrile, and salts thereof. Compounds prepared by the processes of the invention have demonstrated activity as histamine-3 receptor ligands.

Process for preparing amine-substituted benzofurans

The instant invention discloses a process for the synthesis of substituted indole cell proliferation inhibitors.

Process for the preparation of cell proliferation inhibitors

Growing community of inventors

Gurnee, IL, United States of America

Yu-Ming M Pu